|
Judd W. Moul, MD
Director, Duke Prostate Center
Division Chief, Urology
Department / Division:
Surgery / Urology
Training:
* MD, Jefferson Medical College of Thomas Jefferson University (Pennsylvania), 1982
Residency:
* Surgery, Walter Reed Army Medical Center (Washington, DC), 1982-1983
* Urology, Walter Reed Army Medical Center (Washington, DC), 1983-1987
Fellowship:
* Urologic Oncology Fellowship, Duke University Medical Center, 1988-1989
Other Degrees:
* Fellow, American College of Surgeons
* James Semans, MD Professor, 2009
Clinical Interests:
Minimally invasive nerve-sparing radical prostatectomy, treatment of PSA-only or biochemical recurrence of prostate cancer, prostate cancer in African American men, multi-disciplinary management of prostate cancer, clinical trials in prostate disease, noted authority on early stage testicular cancer, international authority on prostate cancer and outcomes/database research; recipient of 2009 Castle Connolly National Physician of the Year for Clinical Excellence
Representative Publications:
Whittemore DE, Hick EJ, Carter MR, Moul JW, Miranda-Sousa AJ, Sexton WJ. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. J Urol. 2008 Feb;179(2):516-22; discussion 522. (2008)
Sun L, Moul JW, Hotaling JM, Rampersaud E, Dahm P, Robertson C, Fitzsimons N, Albala D, Polascik TJ. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int. 2007 Jan 22. (2007)
Scales CD Jr, Curtis LH, Norris RD, Schulman KA, Dahm P, Moul JW. Relationship between body mass index and prostate cancer screening in the United States. J Urol. 2007 Feb;177(2):493-8. (2007)
Mouraviev V, Nosnik I, Sun L, Robertson CN, Walther P, Albala D, Moul JW, Polascik TJ. Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology. 2007 Feb;69(2):311-4. (2007)
Moul JW. Report from durham. Prostate Cancer Prostatic Dis. 2007;10(1):1. (2007)
Moul JW, Sun L, Hotaling JM, Fitzsimons NJ, Polascik TJ, Robertson CN, Dahm P, Anscher MS, Mouraviev V, Pappas PA, Albala DM. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol. 2007 Feb;177(2):499-503; discussion 503-4. (2007)
Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007 Feb;177(2):540-5. (2007)
Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007 Nov 21;298(19):2275-80. (2007)
Xu LL, Sun C, Petrovics G, Makarem M, Furusato B, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW, Srivastava S. Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer Prostatic Dis. 2006;9(1):56-61. (2006)
Tseng TY, Sevilla DW, Moul JW, Maloney KE. Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report. Prostate Cancer Prostatic Dis. 2006;9(2):195-7. (2006)
Scales CD Jr, Curtis LH, Norris RD, Schulman KA, Albala DM, Moul JW. Prostate specific antigen testing in men older than 75 years in the United States. J Urol. 2006 Aug;176(2):511-4. (2006)
Moul JW. Treatment of PSA only recurrence of prostate cancer after prior local therapy. Curr Pharm Des. 2006;12(7):785-98. (2006)
Moul JW. Prostate cancer. Curr Opin Urol. 2006 May;16(3):121-2. (2006)
Moul JW, Ward JF. Management of the Patient with a Rising PSA Alone. Hematol Oncol Clin North Am. 2006 Aug;20(4):897-908. (2006)
Merseburger AS, Hennenlotter J, Simon P, Müller CC, Kühs U, Knüchel-Clarke R, Moul JW, Stenzl A, Kuczyk MA. Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Rep. 2006 Jul;16(1):79-83. (2006)
Freedland SJ, Krupski TL, Moul JW. Update on outcomes research databases in prostate cancer 2006. Curr Opin Urol. 2006 May;16(3):168-72. (2006)
Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology. 2006 Aug;68(2):342-7. (2006)
Anscher MS, Clough R, Robertson CN, Prosnitz LR, Dahm P, Walther P, Donatucci CF, Albala DM, Febbo P, George DJ, Sun L, Moul JW. Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. Prostate Cancer Prostatic Dis. 2006 Aug 1. (2006)
Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005 Oct 1;23(28):6992-8. (2005)
Ward JF, Moul JW. Treating the biochemical recurrence of prostate cancer after definitive primary therapy. Clin Prostate Cancer. 2005 Jun;4(1):38-44. (2005)
Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol. 2005 Apr;2(4):174-82. (2005)
Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol. 2005 May;15(3):187-95. (2005)
Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol. 2005 May;15(3):181-6. (2005)
Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, D'Amico AV. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol. 2005 Sep 20;23(27):6556-60. (2005)
Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem. 2005 Jan;51(1):102-12. (2005)
Petrovics G, Liu A, Shaheduzzaman S, Furasato B, Sun C, Chen Y, Nau M, Ravindranath L, Chen Y, Dobi A, Srikantan V, Sesterhenn IA, McLeod DG, Vahey M, Moul JW, Srivastava S. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005 May 26;24(23):3847-52. (2005)
Moul JW. Screening for prostate cancer in military populations. Mil Med. 2005 Nov;170(11):905-14. (2005)
Moul JW, Zlotta AR. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy. BJU Int. 2005 Feb;95(3):285-90. (2005)
Moul JW, Saad F. Low-risk prostate cancer patient: active treatment. Can J Urol. 2005 Jun;12 Suppl 2:25-7. (2005)
Gu Y, Kim KH, Ko D, Srivastava S, Moul JW, McLeod DG, Rhim JS. Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. Anticancer Res. 2005 Jan-Feb;25(1A):1-8. (2005)
Dahm P, Yang BK, Salmen CR, Moul JW, Gan TJ. Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese patients. J Urol. 2005 Jul;174(1):131-4. (2005)
Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005 Nov 10;23(32):8146-51. (2005)
Brassell SA, Kao TC, Sun L, Moul JW. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology. 2005 Dec;66(6):1229-33. (2005)
Bañez LL, Srivastava S, Moul JW. Proteomics in prostate cancer. Curr Opin Urol. 2005 May;15(3):151-6. (2005)
Shen D, Lao Z, Zeng J, Zhang W, Sesterhenn IA, Sun L, Moul JW, Herskovits EH, Fichtinger G, Davatzikos C. Optimized prostate biopsy via a statistical atlas of cancer spatial distribution. Med Image Anal. 2004 Jun;8(2):139-50. (2004)
Shavers VL, Brown ML, Potosky AL, Klabunde CN, Davis WW, Moul JW, Fahey A. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med. 2004 Feb;19(2):146-55. (2004)
Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 1;22(3):537-56. (2004)
Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, Sesterhenn IA, Srikantan V, Moul JW, Srivastava S. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene. 2004 Jan 15;23(2):605-11. (2004)
Petroski RA, Warlick WB, Herring J, Donahue TF, Sun L, Smith CV, Connelly RR, McLeod DG, Moul JW. External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence. Prostate Cancer Prostatic Dis. 2004;7(2):170-7. (2004)
Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol. 2004 Jun;171(6 Pt 1):2250-4. (2004)
Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004 Mar;171(3):1141-7. (2004)
Moul JW, Chodak G. Combination hormonal therapy: a reassessment within advanced prostate cancer. Prostate Cancer Prostatic Dis. 2004 Sep;7 Suppl 1:S2-7. (2004)
Kirby R, Moul JW. Is the PSA test useless? Prostate Cancer Prostatic Dis. 2004;7(4):271-2. (2004)
Gu Y, Kim KH, Ko D, Nakamura K, Yasunaga Y, Moul JW, Srivastava S, Arnstein P, Rhim JS. A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes. Int J Oncol. 2004 Oct;25(4):1057-64. (2004)
Gilligan T, Manola J, Sartor O, Weinrich SP, Moul JW, Kantoff PW. Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. Clin Prostate Cancer. 2004 Sep;3(2):98-103. (2004)
D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst. 2004 Apr 7;96(7):509-15. (2004)
Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP, Chung AK, McLeod DG. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004 Feb 1;22(3):439-45. (2004)
|
